Cellectis S.A. Files 6-K Report
Ticker: CLLS · Form: 6-K · Filed: Aug 4, 2025 · CIK: 1627281
Sentiment: neutral
Topics: regulatory-filing, 6-K, registration-statement
TL;DR
Cellectis filed a 6-K on Aug 4, 2025, incorporating previous filings into its F-3 and S-8 registration statements.
AI Summary
Cellectis S.A. filed a Form 6-K on August 4, 2025, reporting information as of the same date. This filing is a report of a foreign private issuer and is incorporated by reference into several of Cellectis's registration statements on Form F-3 and Form S-8.
Why It Matters
This filing serves as an update and incorporates previous disclosures into ongoing registration statements, which is crucial for investors tracking the company's regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous information and does not introduce new material events or financial data.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- August 4, 2025 (date) — Filing Date
- 001-36891 (other) — Commission File Number
- Form 6-K (document) — Filing Type
- Form F-3 (document) — Incorporated Registration Statement
- Form S-8 (document) — Incorporated Registration Statement
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer and incorporates information, including Exhibit 99.1, by reference into Cellectis S.A.'s registration statements on Form F-3 and Form S-8.
When was this Form 6-K filed?
This Form 6-K was filed on August 4, 2025.
What is Cellectis S.A.'s commission file number?
Cellectis S.A.'s commission file number is 001-36891.
What type of company is Cellectis S.A. according to its SIC code?
Cellectis S.A. is classified under the SIC code 2836, which pertains to Biological Products (No Diagnostic Substances).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in Paris, France, at 8, rue de la Croix Jarry, 75013.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 4, 2025 regarding Cellectis S.A. (CLLS).